Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram

Myoung J. Choi, Rhee H. Kang, Byung-Joo Ham, Han Yong Jeong, Min-Soo Lee

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The 5-HTR2A gene is a candidate gene for influencing the clinical response to antidepressant treatment. The purpose of this study was to determine the relationship between the -1438A/G polymorphism in the 5-HTR2A gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 4 weeks to the 71 patients who completed this study. We found significant differences in genotype, allele, and carrier distribution between the normal group and MDD patients (genotypes: χ2 = 6.473, d.f. = 2, p = 0.039; alleles: χ2 = 5.589, d.f. = 1, p = 0.018; OR = 0.618, 95% Cl = 0.414-0.922; allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). The frequency of the -1438G allele was much higher in MDD patients than in the normal group (allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). There were also significant differences in response to citalopram according to the -1438A/G variation of 5-HTR2A in MDD patients. The group of remitters carried a higher frequency of the GG allele than of the AA and AG alleles. More of nonremitters carried the A allele than were without it (genotype: χ2 = 8.016, p = 0.018; allele carrier: χ2 = 4.512, p = 0.034; OR = 0.324, 95% Cl = 0.112-0.936). The response to citalopram differed with the -1438A/G polymorphism genotype and allele carriers. The -1438G/-1438G genotype appeared to be associated with a better response to citalopram, with especially the G allele being related to core depressive symptoms and psychic anxiety improvement (p < 0.05). These results suggest that the G allele of the -1438A/G polymorphism in the 5-HTR2A gene is associated with MDD, and that patients with -1438G/-1438G have a better response to citalopram treatment than patients with -1438A/-1438A or -1438A/-1438G.

Original languageEnglish
Pages (from-to)155-162
Number of pages8
JournalNeuropsychobiology
Volume52
Issue number3
DOIs
Publication statusPublished - 2005 Sep 1

Fingerprint

Receptor, Serotonin, 5-HT2A
Citalopram
Alleles
Major Depressive Disorder
Genes
Genotype
Therapeutics
Gene Frequency
Normal Distribution
Antidepressive Agents
Anxiety
Depression

Keywords

  • 5-HTR2A promoter polymorphism
  • Antidepressant
  • Citalopram
  • Major depressive disorder
  • Treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. / Choi, Myoung J.; Kang, Rhee H.; Ham, Byung-Joo; Jeong, Han Yong; Lee, Min-Soo.

In: Neuropsychobiology, Vol. 52, No. 3, 01.09.2005, p. 155-162.

Research output: Contribution to journalArticle

Choi, Myoung J. ; Kang, Rhee H. ; Ham, Byung-Joo ; Jeong, Han Yong ; Lee, Min-Soo. / Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. In: Neuropsychobiology. 2005 ; Vol. 52, No. 3. pp. 155-162.
@article{62c9776ff9c6476b89e66b7b752b585d,
title = "Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram",
abstract = "The 5-HTR2A gene is a candidate gene for influencing the clinical response to antidepressant treatment. The purpose of this study was to determine the relationship between the -1438A/G polymorphism in the 5-HTR2A gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 4 weeks to the 71 patients who completed this study. We found significant differences in genotype, allele, and carrier distribution between the normal group and MDD patients (genotypes: χ2 = 6.473, d.f. = 2, p = 0.039; alleles: χ2 = 5.589, d.f. = 1, p = 0.018; OR = 0.618, 95{\%} Cl = 0.414-0.922; allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95{\%} Cl = 0.249-0.879). The frequency of the -1438G allele was much higher in MDD patients than in the normal group (allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95{\%} Cl = 0.249-0.879). There were also significant differences in response to citalopram according to the -1438A/G variation of 5-HTR2A in MDD patients. The group of remitters carried a higher frequency of the GG allele than of the AA and AG alleles. More of nonremitters carried the A allele than were without it (genotype: χ2 = 8.016, p = 0.018; allele carrier: χ2 = 4.512, p = 0.034; OR = 0.324, 95{\%} Cl = 0.112-0.936). The response to citalopram differed with the -1438A/G polymorphism genotype and allele carriers. The -1438G/-1438G genotype appeared to be associated with a better response to citalopram, with especially the G allele being related to core depressive symptoms and psychic anxiety improvement (p < 0.05). These results suggest that the G allele of the -1438A/G polymorphism in the 5-HTR2A gene is associated with MDD, and that patients with -1438G/-1438G have a better response to citalopram treatment than patients with -1438A/-1438A or -1438A/-1438G.",
keywords = "5-HTR2A promoter polymorphism, Antidepressant, Citalopram, Major depressive disorder, Treatment response",
author = "Choi, {Myoung J.} and Kang, {Rhee H.} and Byung-Joo Ham and Jeong, {Han Yong} and Min-Soo Lee",
year = "2005",
month = "9",
day = "1",
doi = "10.1159/000087847",
language = "English",
volume = "52",
pages = "155--162",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram

AU - Choi, Myoung J.

AU - Kang, Rhee H.

AU - Ham, Byung-Joo

AU - Jeong, Han Yong

AU - Lee, Min-Soo

PY - 2005/9/1

Y1 - 2005/9/1

N2 - The 5-HTR2A gene is a candidate gene for influencing the clinical response to antidepressant treatment. The purpose of this study was to determine the relationship between the -1438A/G polymorphism in the 5-HTR2A gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 4 weeks to the 71 patients who completed this study. We found significant differences in genotype, allele, and carrier distribution between the normal group and MDD patients (genotypes: χ2 = 6.473, d.f. = 2, p = 0.039; alleles: χ2 = 5.589, d.f. = 1, p = 0.018; OR = 0.618, 95% Cl = 0.414-0.922; allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). The frequency of the -1438G allele was much higher in MDD patients than in the normal group (allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). There were also significant differences in response to citalopram according to the -1438A/G variation of 5-HTR2A in MDD patients. The group of remitters carried a higher frequency of the GG allele than of the AA and AG alleles. More of nonremitters carried the A allele than were without it (genotype: χ2 = 8.016, p = 0.018; allele carrier: χ2 = 4.512, p = 0.034; OR = 0.324, 95% Cl = 0.112-0.936). The response to citalopram differed with the -1438A/G polymorphism genotype and allele carriers. The -1438G/-1438G genotype appeared to be associated with a better response to citalopram, with especially the G allele being related to core depressive symptoms and psychic anxiety improvement (p < 0.05). These results suggest that the G allele of the -1438A/G polymorphism in the 5-HTR2A gene is associated with MDD, and that patients with -1438G/-1438G have a better response to citalopram treatment than patients with -1438A/-1438A or -1438A/-1438G.

AB - The 5-HTR2A gene is a candidate gene for influencing the clinical response to antidepressant treatment. The purpose of this study was to determine the relationship between the -1438A/G polymorphism in the 5-HTR2A gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 4 weeks to the 71 patients who completed this study. We found significant differences in genotype, allele, and carrier distribution between the normal group and MDD patients (genotypes: χ2 = 6.473, d.f. = 2, p = 0.039; alleles: χ2 = 5.589, d.f. = 1, p = 0.018; OR = 0.618, 95% Cl = 0.414-0.922; allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). The frequency of the -1438G allele was much higher in MDD patients than in the normal group (allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). There were also significant differences in response to citalopram according to the -1438A/G variation of 5-HTR2A in MDD patients. The group of remitters carried a higher frequency of the GG allele than of the AA and AG alleles. More of nonremitters carried the A allele than were without it (genotype: χ2 = 8.016, p = 0.018; allele carrier: χ2 = 4.512, p = 0.034; OR = 0.324, 95% Cl = 0.112-0.936). The response to citalopram differed with the -1438A/G polymorphism genotype and allele carriers. The -1438G/-1438G genotype appeared to be associated with a better response to citalopram, with especially the G allele being related to core depressive symptoms and psychic anxiety improvement (p < 0.05). These results suggest that the G allele of the -1438A/G polymorphism in the 5-HTR2A gene is associated with MDD, and that patients with -1438G/-1438G have a better response to citalopram treatment than patients with -1438A/-1438A or -1438A/-1438G.

KW - 5-HTR2A promoter polymorphism

KW - Antidepressant

KW - Citalopram

KW - Major depressive disorder

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=24944471356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944471356&partnerID=8YFLogxK

U2 - 10.1159/000087847

DO - 10.1159/000087847

M3 - Article

VL - 52

SP - 155

EP - 162

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 3

ER -